Madrigal Pharmaceuticals
MDGL
268 hedge funds and large institutions have $5.64B invested in Madrigal Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 87 increasing their positions, 78 reducing their positions, and 33 closing their positions.
130% more first-time investments, than exits
New positions opened: 76 | Existing positions closed: 33
23% more capital invested
Capital invested by funds: $4.58B → $5.64B (+$1.06B)
19% more funds holding
Funds holding: 226 → 268 (+42)
12% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 78
5.75% more ownership
Funds ownership: 100.33% → 106.08% (+5.8%)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
1% less call options, than puts
Call options by funds: $372M | Put options by funds: $376M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
+$158M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$97.7M |
| 3 |
PA
Perceptive Advisors
New York
|
+$65.7M |
| 4 |
Morgan Stanley
New York
|
+$32.2M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$29.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$98.5M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$73.5M |
| 3 |
Janus Henderson Group
London,
|
-$70.9M |
| 4 |
Jane Street
New York
|
-$45.2M |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$35.1M |
MDGL Hedge Fund Activity: Q1 2024 in Review
268 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2024, worth a combined $5.64B — up 23% from $4.58B a quarter earlier.
Buyers outnumbered sellers: 76 funds opened new MDGL positions and 33 closed out — a net gain of 43 holders — while 87 added to existing stakes and 78 trimmed.
The largest buyer was Paulson & Co, adding an estimated $158M. The largest seller was RTW Investments, cutting an estimated $98.5M.
- 268 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2024, up from 226 in Q4 2023.
- Funds reported $5.64B of Madrigal Pharmaceuticals stock for Q1 2024, up 23% quarter-over-quarter.
- 76 funds opened new Madrigal Pharmaceuticals positions in Q1 2024 and 33 closed out, a net change of +43 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2024 was Paulson & Co, an estimated $158M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2024 was RTW Investments, an estimated $98.5M sold.
Based on aggregated 13F filings for Q1 2024.